COMPANY

nChroma Bio

HQ: Boston, MA source · nchromabio.com ↗ · New England

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Chronic Hepaititis B CRMA-1001

Timeline

Dec 22, 2025 Trial start 1: A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B source ↗

Dec 31, 2032 (ESTIMATED) · 1 · A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B · NCT07200193

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07200193	A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B	1	Recruiting	Dec 22, 2025	Dec 31, 2032 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗
InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗